In addition, the presence of uncommon and complex EGFR mutations was associated with poorer OS, another typical finding underscoring the representative nature of our cohort and the therapeutic challenges of standard EGFR-TKI therapy for NSCLC with these mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.